Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 20/20 | 1.00 |
| ▸ | SCN7A | Q01118 | 1/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 1/20 | 1.00 |
| ▸ | SCN2A | Q99250 | 1/20 | 1.00 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 1.00 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Funapide SCHEMBL29379143 | 1.00 | SCN9A (1.00) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| Funapide SCHEMBL281394 | 1.00 | SCN9A (1.00) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| Funapide SCHEMBL1612849 | 1.00 | SCN9A (1.00) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL12712202 | 0.94 | SCN9A (0.89) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL2309587 | 0.94 | SCN9A (0.89) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL2305585 | 0.94 | SCN9A (0.89) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL3329910 | 0.93 | SCN9A (0.86) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL2303448 | 0.91 | SCN9A (0.83) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL3331247 | 0.90 | SCN9A (0.82) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL4730724 | 0.90 | SCN9A (0.81) | SCN9ASCN7ASCN5ASCN2ASCN8A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10100060-B2 | Asymmetric synthesis of funapide | XENON PHARMACEUTICALS INC. (CA) | 2018-10-16 | — | — | US | disclosed |
| EP-3266444-A1 | PHARMACEUTICAL COMPOSITIONS OF SPIRO-OXINDOLE COMPOUND FOR TOPICAL ADMINISTRATION AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2018-01-10 | — | — | EP | disclosed |
| US-20180002341-A1 | ASYMMETRIC SYNTHESIS OF FUNAPIDE | PACIRA CRYOTECH, INC. | 2018-01-04 | — | — | US | disclosed |
| WO-2017218920-A1 | ASYMMETRIC SYNTHESIS OF FUNAPIDE | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2017-12-21 | — | — | WO | disclosed |
| EP-2538919-B1 | PHARMACEUTICAL COMPOSITIONS OF SPIRO-OXINDOLE COMPOUND FOR TOPICAL ADMINISTRATION AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2017-07-12 | — | — | EP | disclosed |
| EP-2538919-B1 | PHARMACEUTICAL COMPOSITIONS OF SPIRO-OXINDOLE COMPOUND FOR TOPICAL ADMINISTRATION AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2017-07-12 | — | — | EP | disclosed |
| US-9695185-B2 | Synthetic methods for spiro-oxindole compounds | XENON PHARMACEUTICALS INC. (CA) | 2017-07-04 | — | — | US | disclosed |
| US-9695185-B2 | Synthetic methods for spiro-oxindole compounds | XENON PHARMACEUTICALS INC. (CA) | 2017-07-04 | — | — | US | disclosed |
| US-9695185-B2 | Synthetic methods for spiro-oxindole compounds | XENON PHARMACEUTICALS INC. (CA) | 2017-07-04 | — | — | US | disclosed |
| EP-3156407-A1 | ENANTIOMERS OF SPIRO-OXINDOLE AND THEIR USES AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2017-04-19 | — | — | EP | disclosed |
| US-8445696-B2 | Synthetic methods for spiro-oxindole compounds | XENON PHARMACEUTICALS INC. (CA) | 2013-05-21 | — | — | US | disclosed |
| US-20130072686-A1 | SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2013-03-21 | — | — | US | disclosed |
| US-20130072686-A1 | SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2013-03-21 | — | — | US | disclosed |
| US-20130072537-A1 | ENANTIOMERS OF SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2013-03-21 | — | — | US | disclosed |
| US-20130072537-A1 | ENANTIOMERS OF SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2013-03-21 | — | — | US | disclosed |
| WO-2011047174-A1 | SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2011-04-21 | — | — | WO | disclosed |
| US-20110087027-A1 | SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2011-04-14 | — | — | US | disclosed |
| US-20110087027-A1 | SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2011-04-14 | — | — | US | disclosed |
| US-20100331386-A1 | ENANTIOMERS OF SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-12-30 | — | — | US | disclosed |
| US-20100331386-A1 | ENANTIOMERS OF SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110087027-A1 | SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS | TRPV1, TRPV5, TRPV3 | SCN9A 47/4885SCN7A 44/4885SCN5A 15/4885 |
| US-10100060-B2 | Asymmetric synthesis of funapide | SCN2A, SCN10A, SCN1A | SCN9A 42/4885SCN7A 4/4885SCN5A 71/4885 |
| US-20130072686-A1 | SYNTHETIC METHODS FOR SPIRO-OXINDOLE COMPOUNDS | TRPV1, TRPV5, TRPV3 | SCN9A 47/4885SCN7A 44/4885SCN5A 15/4885 |
| US-20130072537-A1 | ENANTIOMERS OF SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | TRPV1, TRPV5, TRPV3 | SCN9A 21/4885SCN7A 20/4885SCN5A 14/4885 |
| US-20180002341-A1 | ASYMMETRIC SYNTHESIS OF FUNAPIDE | SCN2A, SCN10A, SCN1A | SCN9A 42/4885SCN7A 4/4885SCN5A 71/4885 |
| US-20100331386-A1 | ENANTIOMERS OF SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | TRPV1, TRPV5, TRPV3 | SCN9A 21/4885SCN7A 20/4885SCN5A 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.